<DOC>
	<DOC>NCT00113880</DOC>
	<brief_summary>The purpose of this study was to expand the data describing the safety profile of FluMist in the indicated populations (5-8, 9-17, and 18-49 years of age) and to assess the safety of annual revaccination in those who received FluMist in 2 or more consecutive years.</brief_summary>
	<brief_title>A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults</brief_title>
	<detailed_description>The primary objective of this study was to assess the safety of FluMist vaccination by comparing the rates of medically attended events (MAEs) (including serious adverse events [SAEs], anaphylaxis, urticaria, asthma, wheezing, pre-specified grouped diagnoses, and rare events potentially related to wild-type influenza) in FluMist recipients to rates in multiple non-randomized control groups.</detailed_description>
	<criteria>549 years of age Members of the Kaiser Permanente (KP) Health Care Plan within KP of Northern California, KP of Colorado, and KP of Hawaii Must not have had any high risk underlying medical conditions, includig asthma</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>